Extracorporeal photopheresis alone and with interferon-α(2a) in chronic hepatitis C patients who failed previous interferon therapy

Christopher B O'Brien, Barbara S. Henzel, Dilip K. Moonka, Joanne Inverso, Alain Rook

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Extracorporeal photopheresis (ECP) is approved for treatment of cutaneous, T-cell lymphoma. Evidence suggests that ECP can induce an immune response against tumor antigens expressed by malignant T lymphocytes. We theorized that if HCV-infected PBMCs express viral antigens, ECP could demonstrate antiviral activity by eliciting an immune response against these antigens. Fifteen cirrhotic patients with genotype-1 HCV, who had previously relapsed or not responded to interferon-α (IFN-α) therapy were stratified by their HCV RNA titer into one of three treatment groups: (1) ECP alone, (2) ECP + 3 MIU IFN-α(2a) subcutaneously three times a week and (3) ECP + 6 MIU IFN-α(2a) subcutaneously three times a week. All patients received treatment for 24 weeks. Group 1 had no significant decrease in HCV RNA. Two patients in group 2 had undetectable HCV RNA at the end of treatment. One patient in group 3 had undetectable HCV RNA at the end of treatment. However, HCV RNA was detected in all three patients during follow-up. ECP alone or with IFN- α was well tolerated. ECP alone demonstrated no clear antiviral activity. The combination of ECP and IFN-α resulted in an end-of-treatment response (ETR) in three of 10 patients. All responders had elimination of serum HCV RNA by three months, although no patient had a sustained response. More intensive therapy for a longer duration may result in sustained responses. A multicenter trial is now underway.

Original languageEnglish
Pages (from-to)1020-1026
Number of pages7
JournalDigestive Diseases and Sciences
Volume44
Issue number5
DOIs
StatePublished - May 11 1999

Fingerprint

Photopheresis
Chronic Hepatitis C
Interferons
RNA
Therapeutics
Antiviral Agents
Cutaneous T-Cell Lymphoma
Viral Antigens
Histocompatibility Antigens Class II
Neoplasm Antigens
Multicenter Studies
Genotype

Keywords

  • Chronic hepatitis C
  • Methoxypsoralin
  • Mononuclear cells
  • Photoactivation

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Extracorporeal photopheresis alone and with interferon-α(2a) in chronic hepatitis C patients who failed previous interferon therapy. / O'Brien, Christopher B; Henzel, Barbara S.; Moonka, Dilip K.; Inverso, Joanne; Rook, Alain.

In: Digestive Diseases and Sciences, Vol. 44, No. 5, 11.05.1999, p. 1020-1026.

Research output: Contribution to journalArticle

@article{fae45e43b2084febb2503dac8067b2a7,
title = "Extracorporeal photopheresis alone and with interferon-α(2a) in chronic hepatitis C patients who failed previous interferon therapy",
abstract = "Extracorporeal photopheresis (ECP) is approved for treatment of cutaneous, T-cell lymphoma. Evidence suggests that ECP can induce an immune response against tumor antigens expressed by malignant T lymphocytes. We theorized that if HCV-infected PBMCs express viral antigens, ECP could demonstrate antiviral activity by eliciting an immune response against these antigens. Fifteen cirrhotic patients with genotype-1 HCV, who had previously relapsed or not responded to interferon-α (IFN-α) therapy were stratified by their HCV RNA titer into one of three treatment groups: (1) ECP alone, (2) ECP + 3 MIU IFN-α(2a) subcutaneously three times a week and (3) ECP + 6 MIU IFN-α(2a) subcutaneously three times a week. All patients received treatment for 24 weeks. Group 1 had no significant decrease in HCV RNA. Two patients in group 2 had undetectable HCV RNA at the end of treatment. One patient in group 3 had undetectable HCV RNA at the end of treatment. However, HCV RNA was detected in all three patients during follow-up. ECP alone or with IFN- α was well tolerated. ECP alone demonstrated no clear antiviral activity. The combination of ECP and IFN-α resulted in an end-of-treatment response (ETR) in three of 10 patients. All responders had elimination of serum HCV RNA by three months, although no patient had a sustained response. More intensive therapy for a longer duration may result in sustained responses. A multicenter trial is now underway.",
keywords = "Chronic hepatitis C, Methoxypsoralin, Mononuclear cells, Photoactivation",
author = "O'Brien, {Christopher B} and Henzel, {Barbara S.} and Moonka, {Dilip K.} and Joanne Inverso and Alain Rook",
year = "1999",
month = "5",
day = "11",
doi = "10.1023/A:1026677118006",
language = "English",
volume = "44",
pages = "1020--1026",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "5",

}

TY - JOUR

T1 - Extracorporeal photopheresis alone and with interferon-α(2a) in chronic hepatitis C patients who failed previous interferon therapy

AU - O'Brien, Christopher B

AU - Henzel, Barbara S.

AU - Moonka, Dilip K.

AU - Inverso, Joanne

AU - Rook, Alain

PY - 1999/5/11

Y1 - 1999/5/11

N2 - Extracorporeal photopheresis (ECP) is approved for treatment of cutaneous, T-cell lymphoma. Evidence suggests that ECP can induce an immune response against tumor antigens expressed by malignant T lymphocytes. We theorized that if HCV-infected PBMCs express viral antigens, ECP could demonstrate antiviral activity by eliciting an immune response against these antigens. Fifteen cirrhotic patients with genotype-1 HCV, who had previously relapsed or not responded to interferon-α (IFN-α) therapy were stratified by their HCV RNA titer into one of three treatment groups: (1) ECP alone, (2) ECP + 3 MIU IFN-α(2a) subcutaneously three times a week and (3) ECP + 6 MIU IFN-α(2a) subcutaneously three times a week. All patients received treatment for 24 weeks. Group 1 had no significant decrease in HCV RNA. Two patients in group 2 had undetectable HCV RNA at the end of treatment. One patient in group 3 had undetectable HCV RNA at the end of treatment. However, HCV RNA was detected in all three patients during follow-up. ECP alone or with IFN- α was well tolerated. ECP alone demonstrated no clear antiviral activity. The combination of ECP and IFN-α resulted in an end-of-treatment response (ETR) in three of 10 patients. All responders had elimination of serum HCV RNA by three months, although no patient had a sustained response. More intensive therapy for a longer duration may result in sustained responses. A multicenter trial is now underway.

AB - Extracorporeal photopheresis (ECP) is approved for treatment of cutaneous, T-cell lymphoma. Evidence suggests that ECP can induce an immune response against tumor antigens expressed by malignant T lymphocytes. We theorized that if HCV-infected PBMCs express viral antigens, ECP could demonstrate antiviral activity by eliciting an immune response against these antigens. Fifteen cirrhotic patients with genotype-1 HCV, who had previously relapsed or not responded to interferon-α (IFN-α) therapy were stratified by their HCV RNA titer into one of three treatment groups: (1) ECP alone, (2) ECP + 3 MIU IFN-α(2a) subcutaneously three times a week and (3) ECP + 6 MIU IFN-α(2a) subcutaneously three times a week. All patients received treatment for 24 weeks. Group 1 had no significant decrease in HCV RNA. Two patients in group 2 had undetectable HCV RNA at the end of treatment. One patient in group 3 had undetectable HCV RNA at the end of treatment. However, HCV RNA was detected in all three patients during follow-up. ECP alone or with IFN- α was well tolerated. ECP alone demonstrated no clear antiviral activity. The combination of ECP and IFN-α resulted in an end-of-treatment response (ETR) in three of 10 patients. All responders had elimination of serum HCV RNA by three months, although no patient had a sustained response. More intensive therapy for a longer duration may result in sustained responses. A multicenter trial is now underway.

KW - Chronic hepatitis C

KW - Methoxypsoralin

KW - Mononuclear cells

KW - Photoactivation

UR - http://www.scopus.com/inward/record.url?scp=0032912727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032912727&partnerID=8YFLogxK

U2 - 10.1023/A:1026677118006

DO - 10.1023/A:1026677118006

M3 - Article

C2 - 10235613

AN - SCOPUS:0032912727

VL - 44

SP - 1020

EP - 1026

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 5

ER -